Details of issuance or disposal
Exercise status of the 19th Stock Acquisition Rights issued through third-party allotment (with Exercise Price Adjustment Clause)
New shares: 7,170,000 shares (September 2026 monthly total), including 2,670,000 shares from 11 September to 30 September. Transferred treasury shares: 0 shares
Exercise ratio subject to exercise restrictions: 7.4% (7,170,000 shares delivered across all series / 96,334,098 listed shares outstanding at the time of payment for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 19th Stock Acquisition Rights issued through third-party allotment (with Exercise Price Adjustment Clause) |
| Number of shares to be issued or disposed of | New shares: 7,170,000 shares (September 2026 monthly total), including 2,670,000 shares from 11 September to 30 September. Transferred treasury shares: 0 shares |
| Intended allottee | EVO FUND (allottee of the stock acquisition rights) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 7.4% (7,170,000 shares delivered across all series / 96,334,098 listed shares outstanding at the time of payment for the issuance) |
| Total number of issued shares | 106,464,098 shares (at the end of the month preceding the subject month) → 113,634,098 shares (calculated figure as of month-end) |
| Exercise price | The exercise price in September 2026 was ¥31.0–¥43.0. Details of the adjustment clause and the floor were Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 240,000 units. Exercised during the month: 71,700 units. Currently unexercised balance: 67,000 units (6,700,000 shares) |
| Procedures under the Corporate Code of Conduct | Reports compliance with the exercise restrictions under Article 434 of the Securities Listing Regulations. The exercise ratio subject to the exercise restrictions was 7.4% |
| Most recent equity financing | 12 June 2026: Issuance of the 19th stock acquisition rights (with exercise price adjustment clause), with EVO FUND as the allottee. Amount: Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that it is reporting the large-scale exercise of the 19th stock acquisition rights and their monthly exercise status for September 2026.